Potent LNA oligonucleotides for the inhibition of HIF-1a expression
The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-( T x )G x G x c s a s a s g s c s a s t s c s c s T x G x T -3′ and 5′-( G x )T x T x a s c s t s g s c s c s t s t s c s T x T x A -3′, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues, and subscript “x” designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/LNA nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g. diabetic retinopathy, macular degeneration (ARMD), psoriasis, rheumatoid arthritis and other inflammatory diseases.
1. A method of treating an angiogenic disease selected from macular degeneration and diabetic retinopathy, the method comprising administering to a patient in need thereof a therapeutically effective amount of the LNA oligonucleotide
5′-T s G s G s c s a s a s g s c s a s t s c s c s T s G s T s a-3′ (SEQ ID NO: 1),
wherein the capital letters designate a beta-D-oxy-LNA nucleotide analogue, lower case letters designate a 2-deoxynucleotide, and subscript “s” designates a phosphorothioate link between neighboring nucleotides/LNA nucleotide analogues,
or a conjugate of the LNA oligonucleotide or a composition comprising the LNA oligonucleotide or the conjugate thereof.
2. The method of claim 1 , wherein the LNA oligonucleotide, the conjugate of the LNA oligonucleotide, or the composition is administered parenterally.
3. The method of claim 1 , wherein the LNA oligonucleotide, the conjugate of the LNA oligonucleotide, or the composition is administered intravenously.
4. The method of claim 1 , wherein the LNA oligonucleotide, the conjugate of the LNA oligonucleotide, or the composition is administered by bolus injection into a target organ.